Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2013.31.15_SUPPL.5591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights

  2025cites this paper
• Lenvatinib-refractory thymic mucinous carcinoma with PIK3CA mutation

  2022cites this paper
• Overcoming chemotherapy resistance in endometrial cancer

  2021cites this paper
• Targeted Therapy in Management of Endometrial Cancer

  2019cites this paper
• Molecular-targeted therapies and precision medicine for endometrial cancer.

  2018cites this paper
• Targeting fibroblast growth factor pathways in endometrial cancer.

  2017cites this paper
• Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.

  2016cites this paper
• Recent and current Phase II clinical trials in endometrial cancer: review of the state of art

  2014cites this paper
• Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.

  2014cites this paper